Top Markets
#1 Velas Velas +480.91%
#2 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#3 Siren Siren +107.10%
#4 Venom Venom +47.47%
#5 Gigachad Gigachad +25.21%
#6 Ontology Ontology +20.20%
#7 Scor Scor +17.10%
#8 TRIA TRIA +16.34%
#9 Dacxi Dacxi +16.27%
#10 BabyBoomToken BabyBoomToken +13.98%
Coin of the day
Velas Velas
설정
언어
한국어
통화
USD
테마
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
주식 순위 #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
주가
$0.0416118
시가총액
$12.78M
변동 (1일)
1.72%
변동 (1년)
-22.01%
국가
AU
거래 Noxopharm Limited (NOX)

카테고리

Healthcare
Noxopharm Limited (NOX)의 P/B 비율
March 2026 기준 P/B 비율 TTM: -15.81
Noxopharm Limited의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 -15.81입니다. 2024년 말 기준 P/B 비율은 3.51였습니다.
Noxopharm Limited의 P/B 비율 기록 (2016 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) -15.81 -169.07%
2025 22.89 552.09%
2024 3.51 153.44%
2023 1.39 -41.18%
2022 2.35 -43.58%
2021 4.17 135.34%
2020 1.77 -100.32%
2019 -557.47 -8,922.40%
2018 6.32 -44.76%
2017 11.44 1,140.62%
2016 0.92 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 -135.78%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 -140.38%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -115.53%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -127.60%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 -116.13%
AU